Cubist gains broader fast-track status for antibiotic

05/8/2013 | Boston Herald

The FDA has widened the fast-track status for Cubist Pharmaceuticals' CXA-201 drug to include hospital-acquired bacterial pneumonia and complicated urinary tract infections. The therapy targets pathogens including multidrug resistant Pseudomonas aeruginosa.

View Full Article in:

Boston Herald

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA